Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Baxter Seeks Japan Approval of Recombinant Factor IX for Hemophilia B
January 9, 2014
- Takeda Initiates PIII Trials of Vedolizumab in Japan; Filing Expected in FY2017
January 9, 2014
- Daiichi Sankyo Applies for European Approval of Edoxaban
January 9, 2014
- Former Pfizer EPBU Head Matsumori Joins SBI Biotech as President
January 8, 2014
- Astellas Ties Up with ClearPath in US to Invest in RSV Vaccine Development
January 8, 2014
- NBI Files Additional Indication of Asthma for Spiriva
January 7, 2014
- Eisai Launches Epilepsy Treatment Fycompa in US
January 7, 2014
- Astellas to Transfer Fermentation Research-Related Assets to Taiho
January 7, 2014
- New Price Cut Rule for Long-Listed Products Blow to Drug Makers
January 6, 2014
- Azilva Tops SOC Ranking for Second Month in a Row in November in Both Hospital and GP Markets: Anterio
January 6, 2014
- Novartis Seeks Japanese Regulatory Approval of Psoriasis Agent Secukinumab
January 6, 2014
- Shionogi, AZ Revise Royalty Rate for Crestor
January 6, 2014
- Takeda to End Development of TAK-875 Due to Liver Safety Concerns
December 27, 2013
- Nissan Chemical Sues Seven Generic Companies over Livalo Patents
December 27, 2013
- Ono Files NDA for Nivolumab for Malignant Melanoma
December 27, 2013
- MSD Files NDA for Vaniprevir for Chronic Hepatitis C
December 27, 2013
- Kissei Grants US Pfizer Worldwide Exclusive Rights for Gout and Hyperuricemia Treatment KUX-1151 Outside Japan
December 26, 2013
- Meiji Seika Pharma Scraps Codevelopment Deal with Danish Biotech
December 26, 2013
- Takeda to License Inflammatory Bowel Disease Treatment from US Biotech
December 25, 2013
- Tenelia Now Indicated for Type 2 Diabetes Without Concurrent Use Restrictions
December 25, 2013
ページ
AAV (adeno-associated virus) gene therapies are moving beyond rare diseases into more prevalent conditions, with neovascular, or wet, age-related macular…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…